Pfizer agrees to pay $491 million in drug suit
Pfizers pocketbook is nearly $500 million lighter today.
July 31, 2013 at 05:00 AM
2 minute read
The original version of this story was published on Law.com
Pfizer's pocketbook is nearly $500 million lighter today. The pharmaceutical giant announced that its subsidiary, Wyeth, is pleading guilty to federal charges and will pay $491 million for marketing one of its drugs for uses not approved by the Food and Drug Administration (FDA).
Wyeth pleaded guilty to one count of misbranding Rapamune, a kidney transplant drug, for unapproved uses, including other transplant procedures, the Justice Department said in a statement today. Wyeth will pay a $157.5 million criminal fine, will forfeit assets worth $76 million and will pay another $257 million to resolve civil claims that it trained its staff to market Rapamune for heart, lung, liver and pancreas transplants.
“FDA's drug approval process ensures companies market their products for uses proven safe and effective,” said Stuart F. Delery, Acting Assistant Attorney General for the Justice Department's Civil Division. “We will hold accountable those who put patients' health at risk in pursuit of financial gain.”
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Trending Stories
- 1The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 2Wine, Dine and Grind (Through the Weekend): Summer Associates Thirst For Experience in 'Real Matters'
- 3'That's Disappointing': Only 11% of MDL Appointments Went to Attorneys of Color in 2023
- 4What We Know About the Kentucky Judge Killed in His Chambers
- 5'I'm Staying Everything': Texas Bankruptcy Judge Halts Talc Trials Against J&J
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250